Medicine and Dentistry
Patient
100%
Systemic Lupus Erythematosus
70%
Therapeutic Procedure
53%
Inpatient
43%
Combination Therapy
34%
Vasculitis
31%
Rheumatoid Arthritis
28%
Prednisolone
25%
B Cell
24%
Serum
18%
Methotrexate
18%
Diseases
17%
Interstitial Lung Disease
17%
Odds Ratio
15%
Rituximab
15%
ANCA Associated Vasculitis
15%
Bone Density
14%
Infliximab
14%
Systemic Scleroderma
14%
Quality of Life
14%
Immunosuppressive Drug
14%
Female
14%
Tumor Necrosis Factor
13%
Cytokine
13%
Cytomegalovirus Infection
13%
Antiphospholipid Syndrome
13%
Maintenance Therapy
13%
Cyclophosphamide
12%
Immunosuppressive Treatment
12%
Lymphoid Cell
12%
Cardiac Sarcoidosis
12%
Prostacyclin
12%
Dermatomyositis
12%
Autologous Hematopoietic Stem Cell Transplantation
12%
Comorbidity
12%
Aspergillus
12%
Monocyte
12%
Bleeding
12%
Infection
12%
B Lymphocyte
12%
Positron Emission Tomography
12%
Fluorodeoxyglucose
12%
Interim Analysis
12%
Cohort Analysis
12%
Rheumatic Disease
12%
mRNA Vaccine
12%
Antibody Response
12%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Retrospective Cohort Study
12%
Chemotherapeutic Agent
11%
Immunology and Microbiology
Systemic Lupus Erythematosus
76%
B Cell
36%
Monocyte
33%
Inflammatory Arthritis
31%
Methotrexate
27%
Vasculitis
25%
Lung
25%
CD226
24%
Association
23%
Infliximab
22%
Cells
16%
ANCA Associated Vasculitis
15%
Allele
13%
Comorbidity
12%
Regulatory Cell
12%
Innate Lymphoid Cell
12%
Progranulin
12%
Dermatomyositis
12%
TLR9
12%
Sarcoidosis
12%
Positron Emission Tomography
12%
Tumor Necrosis Factor
12%
Aspergillus
12%
Cytotoxic T-Cell
12%
Immunoglobulin G4 Related Disease
12%
Caspase 1
12%
Pregnancy
12%
Apoptosis
10%
Gene
10%
Systemic Scleroderma
9%
Immunosuppressive Therapy
9%
CXCL9
9%
Cell Adhesion Molecule
9%
Carcinoembryonic Antigen
9%
Joint
9%
TNF Inhibitor
9%
Adalimumab
8%
Microscopic Polyangiitis
8%
Human Leukocyte Antigen
8%
Killer-Cell Immunoglobulin-Like Receptor
8%
Alternative Complement Pathway
8%
Receptor Gene
8%
Pulse Rate
8%
Platelet Count
7%
C-Reactive Protein
7%
Phenotype
6%
Lupus Erythematosus
6%
Inflammatory Disorder
6%
Synovial Fluid
6%
Development
6%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
43%
Methotrexate
30%
Cohort Study
25%
Rheumatoid Arthritis
23%
Disease Activity
23%
Immunosuppressive Agent
22%
Drug
20%
Adverse Event
20%
Mycophenolate Mofetil
19%
Diseases
16%
Prognosis
16%
Prednisolone
16%
Mizoribine
15%
Rituximab
15%
Infliximab
14%
Tumor Necrosis Factor Inhibitor
13%
Folic Acid
13%
Antibody
13%
Vasculitis
13%
Infection
13%
Cytomegalovirus Infection
12%
Tocilizumab
12%
Hydroxychloroquine
12%
Progranulin
12%
Myelodysplastic Syndrome
12%
Aspergillus
12%
Dermatomyositis
12%
Cardiac Sarcoidosis
12%
SARS Coronavirus
12%
Rheumatic Disease
12%
Lupus Vulgaris
11%
Spine Fracture
10%
ANCA Associated Vasculitis
10%
Hemoglobin A1c
10%
Tacrolimus
10%
Interstitial Lung Disease
10%
Aortitis
9%
Pleurisy
9%
Pathogenesis
9%
Fluorodeoxyglucose
9%
Prevalence
8%
C Reactive Protein
8%
Glucocorticoid
8%
Thrombosis
8%
Case Report
8%
Avacopan
8%
Antiphospholipid Antibody
8%
Incidence
7%
Microscopic Polyangiitis
6%
Aspartate Aminotransferase
6%